Site icon Wall Street Business News

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that employees from 16 states participated in the Company’s third annual “Arvinas Impact Day,” a company-wide day of service where employees joined forces to give back to their communities, engaging in various volunteer activities that made a tangible difference across the Greater New Haven area and beyond.

“At Arvinas, we take great pride in aiming to make a positive impact not only in patients’ lives, but also in the communities where we live and work. Arvinas’ third annual Impact Day was a tremendous success, and I’m proud of our employees for their dedication and enthusiasm in supporting vital community organizations,” said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. “This day is a testament to the importance of giving back, aligning with Arvinas’ core values, and fostering a stronger, more inclusive community,” added Dr. Houston. “Through our collective efforts, we can positively impact the lives of others. We look forward to continuing these efforts and supporting our local communities in the years to come.”

This year, employees had the opportunity to participate in a variety of organized projects or to select a local volunteer activity that resonated with their personal values. Together, the Arvinas team made a significant impact.

Highlights from Arvinas Impact Day 2024 include:

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Arvinas Contacts
Media:
Kirsten Owens
203-584-0307
Kirsten.Owens@arvinas.com

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com


Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow